MEETING VENUE
HOTEL MICHELANGELO MILAN
Piazza Luigi di Savoia, 6 - 20124 Milan, Italy
Tel: +39 0267551

MEETING SECRETARIAT AND CME PROVIDER
M&T Srl Viale Carducci, 50 - 40125 Bologna - Italy
Tel. +39 051 220427 Fax +39 051 0822077
info@mitcongressi.it www.mitcongressi.it

REGISTRATION FEE
ELITA/ESOT Member € 100,00 - NonMember € 250,00
to register please access www.mitcongressi.it and click on
ELITA/ESOT Monothematic Conference
LIVER TRANSPLANTATION IN HCV OR HBV POSITIVE RECIPIENTS:
WHERE WE ARE AND WHERE WE ARE GOING

MEETING BOARD

Christophe Duvoux
Chair

Roberto Troisi
Vice-Chair

Wojtek Polak
Secretary

Gabriela Berlakovich
Treasurer

Rene Adam
Custodian

Luca Saverio Belli

William Bennett

Giacomo Germani

Silvio Nadalin

Martin Oliverius

Krzysztof Zieniewicz

ILIVER
TRANSPLANTATION
IN HCV OR HBV
POSITIVE RECIPIENTS:
WHERE WE ARE
AND WHERE WE ARE
GOING

UNRESTRICTED GRANT BY

SILVER SPONSOR

abbvie

Bristol-Myers Squibb

KEDRION
BIOPHARMA

ELITA/ESOT
Monothematic Conference

MILANO
April 1, 2016
HOTEL MICHELANGELO

Luca Saverio Belli

Christophe Duvoux

Scientific Committee

ELITA Board Members
### 8:00> 8:10 Welcome and Introduction: L.S. Belli and C. Duvoux

### 8:10> 8:40 SESSION 1

#### Antiviral therapy for HCV in the setting of Liver transplantation. What’s new since the ELITA Milan Conference 2015

**Chairs:** P. Burra and M. Berenguer

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:10</td>
<td>L.S. Belli and C. Duvoux</td>
</tr>
<tr>
<td>8:40</td>
<td>Summing up of 2015 ELITA guidelines</td>
</tr>
<tr>
<td>8:50</td>
<td>The new weapons and their combinations in early 2016: what will change the landscape in compensated and de-compensated cirrhotics?</td>
</tr>
<tr>
<td>9:00</td>
<td>P. Berg</td>
</tr>
<tr>
<td>9:20</td>
<td>C. Hezode</td>
</tr>
</tbody>
</table>

### 8:40 8:55 SESSION 1

#### The new weapons and their combinations in early 2016: what will change the landscape in compensated and de-compensated cirrhotics?

**Speaker:** T. Berg

### 8:55> 9:05 SESSION 1

#### Up-date on safety, post marketing toxicity and recent alerts of DAAs

**Speaker:** M. Puoti

### 8:55> 9:10 SESSION 1

#### DAAs and virological resistance in the setting of Liver transplantation: pre LT and pre ReLT resistance

**Speaker:** M. Puoti

### 8:55> 9:30 SESSION 1

#### Q&A

### 9:05> 9:10 SESSION 1

#### Use of HCV positive Liver grafts in the DAA Era: can we reconsider it?

**Speaker:** M. Berenguer

### 9:10> 9:30 SESSION 1

#### Value-based Hepatology aspects: the clinician point of view. Focus on pre and post LT DAAs treatments and expected cost reductions

**Speaker:** M. Strazzabosco

### 9:20> 9:40 SESSION 1

#### Q&A

### 9:20> 10:05 SESSION 1

#### HBV/HDV and LT. Data from ELTR

**Speaker:** P. Burro

### 9:30> 9:35 SESSION 1

#### Is there a Virological rationale to combine NUC and HBIG in 2015?

**Speaker:** C. Feray

### 9:40> 9:45 SESSION 1

#### Anti HBC+ve Liver grafts: which prophylaxis in which recipients?

**Speaker:** C. Duvoux

### 9:45> 10:00 SESSION 1

#### HBsAg+ve grafts: which prophylaxis in which recipients?

**Speaker:** P. Andreone

### 9:50> 10:00 SESSION 1

#### HDV and Liver Transplantation: do HDV+ve recipients require a specific prophylaxis?

**Speaker:** M. Rizzetto

### 9:55> 10:10 SESSION 1

#### HDV and Liver Transplantation: do HDV+ve recipients require a specific prophylaxis?

**Speaker:** M. Rizzetto

### 10:05> 10:20 SESSION 1

#### Vaccination for HBV and Liver transplantation: what’s new?

**Speaker:** F. Nevens

### 10:10> 10:30 SESSION 1

#### Q&A

### 10:20> 10:30 SESSION 1

#### HBV infection and Liver transplantation: epidemiology and pre LT management

**Introduction:** C. Duvoux

**Chairs:** P. Muiesan and L. De Carls

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40</td>
<td>Management of HBV: transplant and post transplant issues</td>
</tr>
<tr>
<td>10:50</td>
<td>Is there a Virological rationale to combine NUC and HBIG in 2015?</td>
</tr>
<tr>
<td>11:00</td>
<td>Combined HBIG/NUC prophylaxis: time for selective HBIG withdrawal long term?</td>
</tr>
<tr>
<td>11:10</td>
<td>Is 3rd generation “NUCs alone prophylaxis” after LT a safe option?</td>
</tr>
<tr>
<td>11:20</td>
<td>Just a focus on:</td>
</tr>
<tr>
<td>11:30</td>
<td>Anti HBC+ve Liver grafts: which prophylaxis in which recipients?</td>
</tr>
<tr>
<td>11:40</td>
<td>HBsAg+ve grafts: which prophylaxis in which recipients?</td>
</tr>
<tr>
<td>11:50</td>
<td>HDV and Liver Transplantation: do HDV+ve recipients require a specific prophylaxis?</td>
</tr>
<tr>
<td>12:00</td>
<td>HDV and Liver Transplantation: do HDV+ve recipients require a specific prophylaxis?</td>
</tr>
</tbody>
</table>

### 11:45> 12:10 SESSION 1

#### Controversial aspects of HBV in the Liver transplant setting

**Round table:** M. Rizzetto, M. Berenguer, M. Buti, R. Romagnoli, J. Fung, F. Nevens, F. Durand

### 11:45> 12:00 SESSION 1

#### HBV/HDV and LT. Data from ELTR

**Speaker:** C. Duvoux

### 11:50> 12:15 SESSION 1

#### Impact of NUC therapy on Liver function in decompensated cirrhosis and virological criteria to be eligible for LT

**Speaker:** F. Durand

### 11:55> 12:35 SESSION 1

#### Propylactic strategies in Europe in 2016. French and Italian surveys: the landscape C. Duvoux and R. Volpes

### 12:35> 13:30 SESSION 1

#### Lunch Break

### 12:40> 12:45 SESSION 1

#### An attempt to define the best decision making algorithm for HBV prophylaxis after Liver transplantation

**Speaker:** M. Buti

### 12:45> 13:00 SESSION 1

#### Closing remarks L.S. Belli and C. Duvoux